ArticleElectrophoresis2026
Development of Pentaplex Reverse Transcription Droplet Digital PCR Assay for Simultaneous Detection and Absolute Quantification of HIV-1, HIV-2, HCV, and HBV With Internal Control.
Article in Electrophoresis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
This study presents the development of a pentaplex reverse transcription droplet digital polymerase chain reaction (RT-ddPCR) assay for the simultaneous detection and absolute quantification of human immunodeficiency virus (HIV)-1, HIV-2, hepatitis C virus (HCV), hepatitis B virus (HBV), and an internal control. These viruses are important blood-borne pathogens for diagnostics, blood screening, and the validation of reference materials. Commercial kits used for blood screening allow multiplex detection but rely on relative, cycle threshold-based quantification approaches; consequently, the results may vary depending on reference materials and analytical conditions, which limit interlaboratory comparability. In addition, conventional antigen-antibody assays and single-target quantitative polymerase chain reaction (qPCR) methods have limited multiplexing capability and require standard curves, restricting their broader application. The assay demonstrated 95% limit of detection (LoD) values ranging from 2.42 to 6.65 copies/reaction across targets with high specificity. Validation following the principles outlined in International Organization for Standardization (ISO) 20395:2019 demonstrated the linearity, sensitivity, and precision of the assay, with low coefficients of variation indicating high reproducibility. When evaluated using a nanowell plate-based system, the assay showed comparable performance without statistically significant differences, thereby demonstrating platform scalability. The applicability of the assay was further confirmed using externally sourced pathogen resources, including human plasma-derived HIV-1-positive materials under conditions resembling clinical specimens, demonstrating reliable detection beyond international reference materials. This study introduces a robust multiplex platform for diagnostics, blood screening, and quality control of reference materials. The assay integrates qualitative and quantitative analysis within a single workflow, enabling efficient multi-target detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.